Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2293]
News [4647]
Articles [192]
Editorials [8]
Conferences [136]
elearning [14]
Highlights from WIN 2019
Prof Richard Schilsky - Chief Medical Officer of ASCO and WIN Chairman
Highlights from WIN 2019 ( Prof Richard Schilsky - Chief Medical Officer of ASCO and WIN Chairman )
10 Jul 2019
Goals of the WIN Consortium
Dr Benjamin M. Solomon - Avera Cancer Institute, Sioux Falls, USA
Goals of the WIN Consortium ( Dr Benjamin M. Solomon - Avera Cancer Institute, Sioux Falls, USA )
10 Jul 2019
Rapidly changing landscape of precision medicine in Japan
Dr Sadakatsu Ikeda - Tokyo Medical and Dental University, Tokyo, Japan
Rapidly changing landscape of precision medicine in Japan ( Dr Sadakatsu Ikeda - Tokyo Medical and Dental University, Tokyo, Japan )
10 Jul 2019
Use of platform studies for the evaluation of innovative combinations in solid...
Dr Elizabeth Pease - AstraZeneca, UK
Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies ( Dr Elizabeth Pease - AstraZeneca, UK )
10 Jul 2019
Optimising patient enrolment and efficacy of precision oncology clinical trials
Prof Apostolia-Maria Tsimberidou - The University of Texas MD Anderson Cancer...
Optimising patient enrolment and efficacy of precision oncology clinical trials ( Prof Apostolia-Maria Tsimberidou - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Jul 2019
How will ASCO combat cancer disparities?
Dr Eduardo Cazap, Dr Richard Schilsky
How will ASCO combat cancer disparities? ( Dr Eduardo Cazap, Dr Richard Schilsky )
21 Jun 2019
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...
Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
20 Jun 2019
HORIZON update: Using melflufen to treat RRMM patients refractory to...
Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
20 Jun 2019
Chemoimmunotherapy or BTK inhibition for patients with CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )
20 Jun 2019
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Using bioinformatics and genomics to treat AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019
The changing landscape of AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation